MIRUM PHARMAC. DL-,0001 Aktie

Mirum Pharmaceuticals stock rose to an all-time high of 125.41 USD, bringing market capitalization to about 7.6 billion USD after a one-year gain of roughly 147%. InvestingPro rates the stock as significantly overvalued versus its fair-value estimate, despite reported revenue growth of around 50% in the last twelve months. Mirum placed convertible notes totaling 600 million USD (0.00% coupon, maturing 2032) and received several analyst price targets between 145 and 185 USD; the company also acquired zilurgisertib from Incyte for 16 million USD. » More on de.investing.com

Mirum Pharmaceuticals is evolving from the maker of LIVMARLI into a diversified specialty pharma company with a pipeline revenue opportunity of over USD 4 billion. Phase 2 data on zilurgisertib and primary endpoints for volixibat and brelovitug support the expansion plans. In the first quarter revenue rose by more than 43% and the full-year guidance was raised to USD 660–680 million, or growth of up to 30%. » More on finanzen.net

Citizens increased its price objective for Mirum Pharmaceuticals to $146, citing promising clinical activity from the recently acquired zilurgisertib program in fibrodysplasia ossificans progressiva (FOP). Although the Phase 2b study missed its primary endpoint, supplemental data bolstered the view that the therapy could still advance toward regulatory approval and have attractive commercial potential. Separately, Mirum approved inducement equity awards for new hires, reflecting ongoing organizational investment as it pursues rare-disease expansion. » More on finance.yahoo.com